Abstract
Two approaches to genetic therapy for the management of chronic pain have recently been investigated in animal models of pain. First, transgene-mediated delivery of antinociceptive molecules to the cerebrospinal fluid has been performed with engineered cell lines transplanted to the subarachnoid space and with recombinant adenoviruses that transduce pia mater cells. Second, the phenotype of nociceptive neurons has been altered by recombinant herpes viruses overexpressing antinociceptive peptides or reducing expression of endogenous nociceptive molecules. Both approaches attenuate or reverse persistent nociceptive states, suggesting use in the development of genetic therapy for pain management in humans.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Costantini LC, Bakowska JC, Breakefield XO, Isacson O: Gene therapy in the CNS. Gene Ther 2000, 7:93–109. This is an excellent review of virus-based gene transfer directed toward the nervous system.
During MJ, Ashenden LM: Towards gene therapy for the central nervous system. Mol Med Today 1998, 4:485–493.
Czech KA, Sagen J: Update on cellular transplantation into the CNS as a novel therapy for chronic pain. Prog Neurobiol 1995, 46:507–529.
Eaton MJ, Santiago DI, Dancausse HA, Whittemore SR: Lumbar transplants of immortalized serotonergic neurons alleviate chronic neuropathic pain. Pain 1997, 72:59–69.
Cejas PJ, Martinez M, Karmally S, et al.: Lumbar transplant of neurons genetically modified to secrete brain-derived neurotrophic factor attenuates allodynia and hyperalgesia after sciatic nerve constriction. Pain 2000, 86:195–210. This article describes the effects of brain-derived neurotrophic factor delivery to the cerebrospinal fluid when tested in rats with chronic constriction injury of the sciatic nerve.
Eaton MJ, Plunkett JA, Martinez MA, et al.: Transplants of neuronal cells bioengineered to synthesize GABA alleviate chronic neuropathic pain. Cell Transplant 1999, 8:87–101. This article demonstrates that simply increasing the levels of the inhibitory neurotransmitter g-aminobutyric acid in cerebrospinal fluid is sufficient to reduce allodynia and hyperalgesia associated with chronic constriction injury of the sciatic nerve in rats. Basic information about the engineered cell line used for transgene delivery is provided.
Eaton MJ, Karmally S, Martinez MA, et al.: Lumbar transplant of neurons genetically modified to secrete galanin reverse pain-like behaviors after partial sciatic nerve injury. J Peripher Nerv Syst 1999, 4:245–257. This paper demonstrates that low-level galanin release into the cerebrospinal fluid is anti-allodynic and antihyperalgesic in the rat chronic constriction injury model.
Zhang X, Xu ZO, Shi TJ, et al.: Regulation of expression of galanin and galanin receptors in dorsal root ganglia and spinal cord after axotomy and inflammation. Ann N Y Acad Sci 1998, 863:402–413.
Hagihara Y, Saitoh Y, Arita N, et al.: Long-term functional assessment of encapsulated cells transfected with Tet-On system. Cell Transplant 1999, 8:431–434.
Saitoh Y, Eguchi Y, Hagihara Y, et al.: Dose-dependent doxycycline-mediated adrenocorticotropic hormone secretion from encapsulated Tet-on proopiomelanocortin Neuro2A cells in the subarachnoid space. Hum Gene Ther 1998, 9:997–1002.
Finegold AA, Mannes AJ, Iadarola MJ: A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther 1999, 10:1251–1257. This paper describes the construction of an adenovirus encoding a precursor for secreted b-endorphin and the effects of its subarachnoid delivery.
Cheng PY, Liu-Chen LY, Pickel VM: Dual ultrastructural immunocytochemical labeling of mu and delta opioid receptors in the superficial layers of the rat cervical spinal cord. Brain Res 1997, 778:367–380.
Zhang X, Bao L, Arvidsson U, et al.: Localization and regulation of the delta-opioid receptor in dorsal root ganglia and spinal cord of the rat and monkey: evidence for association with the membrane of large dense-core vesicles. Neuroscience 1998, 82:1225–1242.
Wilson SP, Yeomans DC, Bender MA, et al.: Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci U S A 1999, 877:751–755. This paper demonstrates that overexpression of an opioid peptide precursor in skin primary afferents is antihyperalgesic for 3 to 4 months. It suggests that phenotypic modification of sensory neurons is a useful approach to pain management.
Bras JMA, Epstein AL, Bourgoin S, et al.: Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem 1998, 70:1299–1303.
Palmer JA, Branston RH, Hunt SP, et al.: Investigation of the role of neurotrophins in chronic pain states using herpes simplex virus based vectors. Soc Neurosci Abstr 1999, 25:1945.
Yeomans DC, Proudfit HK: Characterization of the foot withdrawal response to noxious radiant heat in the rat. Pain 1994, 59:85–94.
Yeomans DC, Proudfit HK: Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: electrophysiological evidence. Pain 1996, 68:141–150.
Yeomans DC, Pirec V, Proudfit HK: Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: behavioral evidence. Pain 1996, 68:133–140.
Womer DE, DeLapp NW, Shannon HE: Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice. Pain 1997, 70:223–228.
Amin S, Wilson S, Laurito C, et al.: Opioid gene transfer using herpes vectors reverses intrathecal pertussis toxininduced hyperalgesia in mice. Soc Neurosci Abstr 1998, 24:892.
Fink DJ, Goins WF, Glorioso JC, Goss JR: Analgesic effects of a modified herpes simplex virus expressing human preproenkephalin in rats. Soc Neurosci Abstr 1999, 25:924.
Lu Y, Wilson SP, Yeomans DC: Antihyperalgesic effects of infection of mouse skin with a herpes virus which encodes antisense for CGRP. Soc Neurosci Abstr 1998, 24:1625.
Yeomans DC, Lu Y, Laurito C, et al.: Stimulus-dependent analgesia after application of a transgenic herpes virus encoding human proenkephalin to primate skin. Soc Neurosci Abstr 1999, 25:924.
Romero MI, Rangappa N, Li L, et al.: Extensive sprouting of sensory afferents and hyperalgesia induced by conditional expression of nerve growth factor in the adult spinal cord. J Neurosci 2000, 20:4435–4445.
Mannes AJ, Caudle RM, O’Connell BC, Iadarola MJ: Adenoviral gene transfer to spinal-cord neurons: intrathecal vs. intraparenchymal administration. Brain Res 1998, 793:1–6.
Kang W, Wilson MA, Bender MA, et al.: Herpes virusmediated preproenkephalin gene transfer to the amygdala is antinociceptive. Brain Res 1998, 792:133–135.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wilson, S.P., Yeomans, D.C. Genetic therapy for pain management. Current Review of Pain 4, 445–450 (2000). https://doi.org/10.1007/s11916-000-0068-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11916-000-0068-5